Verastem Oncology drops despite Q3 double beat
Source: SeekingAlpha
2025-11-04 12:12:01 ET
More on Verastem
- Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript
- Verastem, Inc. 2025 Q3 - Results - Earnings Call Presentation
- Verastem: Navigating Critical Steps In Commercialization And Development (Downgrade)
- Verastem signals confidence in AVMAPKI FAKZYNJA CO-PACK growth and prepares for pivotal 2026 clinical milestones
- Verastem Q3 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Verastem Oncology drops despite Q3 double beat
Verastem Inc.
NASDAQ: VSTM
VSTM Trading
-5.08% G/L:
$5.9517 Last:
647,593 Volume:
$6.19 Open:
VSTM Latest News
VSTM Stock Data
$424,027,638
66,108,246
1.4%
15
N/A
Biotechnology & Life Sciences
Healthcare
US
Needham
